Paper Details

  1. Home
  2. Paper Details

Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.

Author: AravagiriM, HawesE M, HubbardJ W, MarderS R, McKayG, MidhaK K, MintzJ, Van PuttenT

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Fluphenazine decanoate, a long-acting antipsychotic, required three months to reach a steady-state plasma level in patients receiving 25 mg every two weeks. Lower fluphenazine plasma levels were associated with an increased risk of psychotic exacerbations.
Paper Details　
Original Abstract of the Article :
The levels of fluphenazine and fluphenazine sulphoxide in schizophrenic patients who were randomly assigned to receive either 5 mg or 25 mg of fluphenazine decanoate every two weeks were monitored. Patients treated with 25 mg of fluphenazine decanoate required three months to reach a steady-state pl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1192/bjp.158.5.658

データ提供：米国国立医学図書館（NLM）

Fluphenazine Decanoate: Navigating the Shifting Sands of Schizophrenia Treatment

The vast desert of schizophrenia treatment is a challenging landscape, with many paths leading to varying degrees of success. This research focuses on the long-term use of fluphenazine decanoate, a depot antipsychotic, and its impact on clinical response, side effects, and patient compliance.

The authors meticulously monitored plasma levels of fluphenazine and its metabolite in patients receiving either 5 mg or 25 mg of fluphenazine decanoate every two weeks. They observed a correlation between lower fluphenazine levels and an increased risk of psychotic exacerbations, suggesting the importance of maintaining therapeutic levels for long-term stability. However, the relationship between fluphenazine levels and neurological side effects, such as akinesia, akathisia, retardation, and tardive dyskinesia, was less clear-cut.

Finding a Stable Oasis: Understanding Fluphenazine Levels in Schizophrenia

This research provides valuable insights into the complex interplay between fluphenazine levels and clinical outcomes in schizophrenia. The authors' findings highlight the importance of maintaining therapeutic levels, especially in the long term, to minimize the risk of relapses and optimize treatment outcomes.

Navigating the Desert of Medication Management: Balancing Effectiveness and Side Effects

This study underscores the importance of careful medication management in schizophrenia. The authors' observations regarding the relationship between fluphenazine levels and both clinical response and side effects emphasize the need for a nuanced approach, balancing effectiveness with minimizing unwanted side effects. This approach can help patients navigate the challenging desert of medication management.

Dr. Camel's Conclusion

This research reminds us that even in the vast desert of schizophrenia treatment, where countless paths lead to varying outcomes, there are oases of knowledge to guide us. The authors' meticulous exploration of fluphenazine decanoate provides valuable insights into medication management, emphasizing the importance of achieving a delicate balance between effectiveness and minimizing side effects.

Date :
  1. Date Completed 1991-09-05
  2. Date Revised 2019-07-05
Further Info :

Pubmed ID

1860020

DOI: Digital Object Identifier

10.1192/bjp.158.5.658

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.